Shajini
Metsera’s board has deemed Novo Nordisk’s $10 billion bid superior to Pfizer’s, setting off a high-stakes bidding and legal battle amid the obesity-drug gold rush.
HRSA’s approval of eight manufacturers for its 340B Rebate Model Pilot signals a major pricing shift.
From October 27, 2025, patients in the Netherlands with spinal metastases or multiple myeloma can access bone cement injections.
Manifold Bio inks a groundbreaking collaboration with Roche to apply AI-guided brain-shuttle technology for neurological therapies.
The New Frontier of Gene Editing: From Precision Tools to Personalized Therapies A new generation of programmable gene editing tools is pushing biotechnology toward an era of truly personalized medicine one in which therapies are tailored not only to specific diseases but to individual genetic profiles. As highlighted in a recent npj Biomedical Innovations feature … Read more
Pfizer’s GLP-1 lawsuit tests biosimilar ambitions and contract guardrails.
Cardiac MRI is proving its place as a powerful, radiation-free alternative to SPECT in diagnosing coronary artery disease.
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more